Needham upgraded Amphastar (AMPH) (APMH) to Buy from Hold with a $36 price target. The company’s AMP-002 is an iron sucrose injection product that received FDA approval as an equivalent to Venofer, a $515M annual sales product, the analyst tells investors in a research note. The firm says the only downside to the approval is an equivalent generic product by Viatris (VTRS) was also approved. Needham cites valuation for the upgrade of Amphastar and believes AMP-002 sales should help the company at least meet growth expectations for 2025 and 2026.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMPH:
- Amphastar upgraded to Buy from Hold at Needham
- Amphastar Pharmaceuticals Enters Strategic Licensing Agreement
- Cautious Hold Rating on Amphastar Pharmaceuticals Amid Uncertain Product Approvals and Flat Revenue Growth
- Amphastar price target lowered to $25 from $30 at Piper Sandler
- Amphastar Pharmaceuticals Reports Q2 2025 Earnings Highlights